Multiple Myeloma News
Transient Responses Observed With BCMA-Targeted Retreatment in MM
Source: Myeloma - Hematology Advisor BCMA-directed chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies can produce transient responses in patients with multiple myeloma (MM) whose disease relapsed on prior BCMA-directed CAR T-cell therapy,...
FDA Oncologic Drugs Advisory Committee Votes in Favor of Cilta-Cel as Early Treatment for Multiple Myeloma
Source: Myeloma - Hematology Advisor In a meeting of the Oncologic Drugs Advisory Committee (ODAC), the committee of 11 members unanimously voted that the potential benefits of ciltacabtagene autoleucel (cilta-cel) outweigh its risks for its proposed indication.1 The...
Study Finds COQ2 Essential for Multiple Myeloma Proliferation, Affects Sensitivity to Cell Death
Source: Pharmacy Times articles The study authors are hopeful that this finding can help in the development of new drugs or treatments for patients with multiple myeloma. Read More
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Source: Myeloma : nature.com subject feeds Post Content Read More
Novel Model Effectively Predicts Early Relapse After CAR-T Therapy in Myeloma
Source: Myeloma - Hematology Advisor A novel prognostic model may aid in the timing of chimeric antigen receptor (CAR) T-cell therapy among patients with relapsed or refractory multiple myeloma (MM), according to research published in the Journal of Clinical Oncology....
Promising drug combination for multiple myeloma treatment
New research has found that venetoclax, a medication currently approved for leukemia, has benefits for patients with multiple myeloma when used in combination with another drug. This discovery offers a new avenue of treatment options for the currently incurable...
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Source: Myeloma : nature.com subject feeds Post Content Read More
Study Identifies Factors Linked to Unsustained MRD in Multiple Myeloma
Source: Myeloma - Hematology Advisor In transplant-eligible patients with newly diagnosed multiple myeloma (MM), a recent study identified factors related to whether measurable residual disease (MRD) negativity was sustained over time. Study results were reported in...
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Source: Myeloma : nature.com subject feeds Post Content Read More